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Abstract
Background: Marek’s disease (MD) is a lymphoproliferative disease in chickens caused by Marek’s disease virus
(MDV) and characterized by T cell lymphoma and infiltration of lymphoid cells into various organs such as liver,
spleen, peripheral nerves and muscle. Resistance to MD and disease risk have long been thought to be influenced
both by genetic and environmental factors, the combination of which contributes to the observed outcome in an
individual. We hypothesize that after MDV infection, genes related to MD-resistance or -susceptibility may exhibit
different trends in transcriptional activity in chicken lines having a varying degree of resistance to MD.
Results: In order to study the mechanisms of resistance and susceptibility to MD, we performed genome-wide
temporal expression analysis in spleen tissues from MD-resistant line 63, susceptible line 72 and recombinant
congenic strain M (RCS-M) that has a phenotype intermediate between lines 63 and 72 after MDV infection. Three
time points of the MDV life cycle in chicken were selected for study: 5 days post infection (dpi), 10dpi and 21dpi,
representing the early cytolytic, latent and late cytolytic stages, respectively. We observed similar gene expression
profiles at the three time points in line 63 and RCS-M chickens that are both different from line 72. Pathway
analysis using Ingenuity Pathway Analysis (IPA) showed that MDV can broadly influence the chickens irrespective of
whether they are resistant or susceptible to MD. However, some pathways like cardiac arrhythmia and
cardiovascular disease were found to be affected only in line 72; while some networks related to cell-mediated
immune response and antigen presentation were enriched only in line 63 and RCS-M. We identified 78 and 30
candidate genes associated with MD resistance, at 10 and 21dpi respectively, by considering genes having the
same trend of expression change after MDV infection in lines 63 and RCS-M. On the other hand, by considering
genes with the same trend of expression change after MDV infection in lines 72 and RCS-M, we identified 78 and
43 genes at 10 and 21dpi, respectively, which may be associated with MD-susceptibility.
Conclusions: By testing temporal transcriptome changes using three representative chicken lines with different
resistance to MD, we identified 108 candidate genes for MD-resistance and 121 candidate genes for MD-
susceptibility over the three time points. Genes included in our resistance or susceptibility genes lists that are also
involved in more than 5 biofunctions, such as CD8a, IL8, USP18, and CTLA4, are considered to be important genes
involved in MD-resistance or -susceptibility. We were also able to identify several biofunctions related with immune
response that we believe play an important role in MD-resistance.
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Background
MD is a serious lymphoproliferative disease in chickens
caused by MDV and characterized by transformation of
T cells that cause tumors in various organs including
liver, spleen, gonads, heart, peripheral nerves, skin and
muscle [1-3]. Chickens with MD exhibit over-expression
of Hodgkin’s disease antigen CD30 (CD30hi) that makes
it a natural model for studying the initiation and pro-
gression of CD30hi lymphomas [4]. MDV is an alphaher-
pesvirus belonging to the Mardivirus genus which
contains three members: MDV-1, MDV-2 and HVT
(herpesvirus of turkeys) [5-7]. According to Calnek et al.
[8,9], MDV, like other herpesviruses, goes through a
complex life cycle that includes cytolytic and latent
phases in host cells. An early cytolytic infection is
started at 2-7dpi characterized by the virus particles
expressing large amounts of the early protein pp38. Sub-
sequently, a latent phase is initiated at around 7-10dpi
with the MDV genome persisting in the host cells. Fol-
lowing latency, a late cytolytic phase causes inflamma-
tion and transformation of latently infected lymphocytes
into tumor cells and is triggered between 14-21dpi [8,9].
During the first cytolytic phase, MDV first uses B cells
as a target for its replication before targeting activated
CD4+ T cells to enable a persistent latent infection
[10-12].
Two highly inbred chicken lines 63 and 72, sub-lines
of lines 6 and 7, have been bred since 1939 with line 63
chickens resistant to MD and line 72 chickens suscepti-
ble to MD [13]. To better understand the mechanisms
underlying MD-resistance and -susceptibility, several
studies have been made to ascertain the differences
between these two chicken lines. A much higher virus
copy number was observed in line 7 chickens indicating
varying levels of virus replication [14]. Different propor-
tions of CD4+ T cells and CD8+ T cells were found in
MD-resistant and -susceptible chickens when infected
by MDV. In MD-susceptible birds, as the CD4+ T cells
increased in number, the number of CD8+ T cells
decreased; the opposite occurred in MD-resistant chick-
ens [15]. Lymphocyte surface markers such as Ly-4, Bu-
1 and Th-1, were present in different levels in these two
chicken lines [16,17]. The expression of some cytokines,
such as IL6 and IL18, was also found to differ between
line 6 and line 7 chickens[18]. From an epigenetic per-
spective, differences in promoter DNA methylation
levels between line 63 and line 72 chickens have been
found in several candidate genes [19].
With the development of functional genomics technol-
ogies, some progress has been made towards investigat-
ing the mechanism of MD-resistance in a genome-wide
manner. Quantitative trait loci associated with MD-
resistance or -susceptibility have been mapped to chro-
mosomes 1, 5, 7, 9, 15, 18, 26, Z, E21 and E16 [20-23].
Also, through the use of chicken immune-specific
microarrays, immunoglobulin genes have been shown to
have a higher expression in MD-resistant chicken lines
as compared to MD-susceptible chicken lines [24].
However, the exact mechanisms behind resistance and
susceptibility to MD are still unknown.
Researchers at the Avian Disease and Oncology
Laboratory (ADOL, East Lansing, MI, USA) have devel-
oped nineteen recombinant congenic strains (RCS) with
varying phenotypic traits from lines 63 and 72 to further
investigate the mechanisms of MD-resistance and - sus-
ceptibility [13,25]. One of these strains, RCS-M, which
was developed from line 63 and line 72 and possesses
around 87% genetic background of line 63, is genetically
closer to the resistant line 63. Our previous study of
tumor incidence rates induced by a partially attenuated
very virulent plus (vv+) strain of MDV (648A, passage
40) in the different RCSs revealed that while only 0-3%
of line 63 chickens and up to 100% of the line 72 chick-
ens developed tumors after MDV infection, about 40%
of RCS-M chickens developed tumors (Data not shown).
Because of this intermediate response of RCS-M to
MDV infection, it is suitable for us to use these three
chicken lines to investigate the mechanism of MD-resis-
tance and susceptibility. We performed a temporal tran-
criptome analysis with spleen samples from line 63, 72
and RCS-M chickens before and after MDV infection at
5dpi, 10dpi and 21dpi. Our main objective is to build on
the current understanding of Marek’s disease pathogen-
esis and immune response to MDV, and this genome-
wide approach is used for this purpose. To our knowl-
edge, this is the first comprehensive study combining a
chicken line having intermediate resistance to MD
together with highly-resistant and susceptible lines to
more precisely identify the possible genetic factors
behind MD resistance and susceptibility.
Results
Temporal Gene Expression Profiles of line 63, line 72 and
line M chickens in MDV Challenge Experiment
To find genes that may be involved in the MD-resis-
tance and -susceptibility, we performed transcriptome
analysis using three chicken lines with different pheno-
types after MDV infection to find the host genes with
different reactions to virus infection. We chose 5dpi,
10dpi and 21dpi to represent the critical phases of virus
progression to study gene expression changes induced
in the different chicken lines.
We conducted an initial quality assessment of our
dataset to remove outliers (see Methods). Principal com-
ponent analysis (PCA) was used to compare the global
gene expression profiles of these three chicken lines.
The preliminary PCA plot indicated broad differences
between the three chicken lines with lines 63 and RCS-
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M clustering together and distinct from line 72 chickens
(Figure 1). Data normalization and differential gene
expression analysis was performed using the limma
package in R (for details see Methods). In order to mini-
mize transcriptional variations owing to growth and
other developmental differences between the three
chicken lines, individuals were paired by line and dpi
and comparisons carried out between infected and non-
infected individuals. The p-values were then corrected
for multiple comparisons using the Benjamini-Hochberg
FDR calculation procedure [26]. To detect the host
response to MDV infection, we compared the gene
expression level of the infected samples to non-infected
control samples at the same time point. Differentially
expressed gene lists were obtained using a criteria of P
< 0.05, FDR < 0.5 and |logFC| > 1.5.
Our significant gene lists consisted of a total of 11779
genes in the three chicken lines across three time points
that included some virus genes contained in the micro-
array (Additional file 1. Table S1). As our focus was on
the host response to MDV infection, we excluded the
MDV genes from further analysis reducing our total
gene number to 11694 (Table 1). Notably, no gene was
found differentially expressed in line 72 at 5dpi using
the above criteria. However, when validating the micro-
array results with qPCR, we found several genes signifi-
cantly changed by MDV infection in line 72 at 5dpi
(Additional file 2. Figure S1).
Pathway analysis to find the networks and biofunctions
involved in MDV infection
To study the networks and biofunctions enriched in the
differentially expressed genes after MDV infection, we
used the IPA system to analyze genes sets. We first used
the raw probe names from the microarray as the input
data set and found less than 25% of the probes were
compatible with IPA. Therefore, we used data mining to
map the probe names to homologs from other species
that could be used by IPA (for details see Methods).
The mapped homologs of these ESTs are shown in
Additional file 3. Table S2.
Detailed analyses of the networks and biofunctions
affected by MDV in the different chicken lines across
different time points were performed to understand the
host responses to MDV infection. The top 5 networks
influenced by MDV infection in each chicken line at
three time points are shown in Table 2. From these net-
works we can see that during various stages of the
MDV life cycle (5dpi, 10dpi and 21dpi), the virus has a
broad influence on host gene expression in all chicken
lines. A large number of genes involved in metabolism,
tissue development, gene expression and the cell cycle
were changed by MDV infection in all chicken lines
which indicated broad similarities in the host response
to MDV infection. However, we also found some unique
networks among these chicken lines, such as, cardiac
arrhythmia and cardiovascular disease related networks
found only in line 72. On the other hand, some
immune-related networks such as cell-mediated immune
response and antigen presentation were only found in
line 63 and RCS-M but not in line 72. These are the spe-
cific responses to MDV infection which may be related
to the genetic basis of MD-resistance and -susceptibility.
Identification of genes related with MD-resistance and
-susceptibility
Utilizing the varying characteristics of these chicken
lines, we attempted to identify genes associated with
MD-resistance and -susceptibility from pair-wise com-
parisons. We make the following observations about dif-
ferentially expressed genes obtained from our analysis.
Genes differentially expressed after MDV infection and
having similar trends in line 63 and RCS-M but not in
line 72 are likely to be related to MD-resistance; conver-
sely, genes showing similar trends in line 72 and RCS-M
Figure 1 A three-dimensional PCA plot of 64 individuals
indicating broad transcriptional similarities between line 63
and RCS-M that are both markedly distinct from line 72.
Table 1 Number of genes differentially expressed after
MDV infection
line 63
(Inf. Vs. Non.)
line 72
(Inf. Vs. Non.)
RCS-M
(Inf. Vs. Non.)
+ - + - + -
5dpi 777 651 0 0 707 680
10dpi 708 660 823 691 791 572
21dpi 573 585 1007 1088 567 814
Genes with differential expression were termed with P < 0.05, |LogFC|>1.5 and
FDR < 0.5. +: up-regulated after MDV infection; -: down-regulated after MDV
infection.
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Table 2 Enriched networks at different time points of MDV infection in different chicken lines
Lines Time
points
Score Focus
Molecules
Top Functions
L63 5dpi 46 29 Digestive System Development and Function, Hepatic System
Development and Function, Organ Development
36 25 Skeletal and Muscular System Development and Function, Tissue
Morphology, Lipid Metabolism
35 25 Amino Acid Metabolism, Small Molecule Biochemistry, Cellular
Compromise
28 21 Carbohydrate Metabolism, Lipid Metabolism, Small Molecule
Biochemistry
24 20 Drug Metabolism, Endocrine System Development and Function, Lipid
Metabolism
10dpi 36 25 Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral
Metabolism
30 21 Infection Mechanism, Visual System Development and Function,
Dermatological Diseases and Conditions
30 21 Molecular Transport, Cellular Movement, Cell Cycle
27 22 Neurological Disease, Carbohydrate Metabolism, Lipid Metabolism
26 19 Organismal Injury and Abnormalities, Infection Mechanism, Infectious
Disease
21dpi 39 28 Cell Morphology, Cellular Function and Maintenance, Cell Death
34 22 Cardiovascular System Development and Function, Organismal
Development, Tissue Development
27 19 Carbohydrate Metabolism, Small Molecule Biochemistry, Cellular
Assembly and Organization
24 17 Cell-To-Cell Signaling and Interaction, Cell-mediated Immune
Response, Cellular Development
22 16 Lipid Metabolism, Small Molecule Biochemistry, Behavior
L72 10dpi 29 21 Cardiac Arrythmia, Cardiovascular Disease, Genetic Disorder
27 22 Cellular Assembly and Organization, Cellular Compromise, Free
Radical Scavenging
26 19 Cell-To-Cell Signaling and Interaction, Cellular Growth and
Proliferation, Skeletal and Muscular System Development and Function
24 18 Cell Morphology, Connective Tissue Development and Function,
Skeletal and Muscular System Development and Function
22 17 Infection Mechanism, Cardiovascular System Development and
Function, Organismal Development
21dpi 38 27 Cell Morphology, Connective Tissue Development and Function,
Skeletal and Muscular System Development and Function
32 24 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry
31 24 Embryonic Development, Tissue Development, Cell Cycle
31 24 Cell Morphology, Skeletal and Muscular System Development and
Function, Connective Tissue Development and Function
23 20 Connective Tissue Disorders, Genetic Disorder, Cellular Assembly and
Organization
RCS- M 5dpi 32 22 Cell Morphology, Cellular Development, Cell Death
32 22 Cellular Assembly and Organization, Cell Morphology, Cellular
Development
30 21 Cell Morphology, Cellular Development, Skeletal and Muscular System
Development and Function
28 20 Amino Acid Metabolism, Small Molecule Biochemistry, Drug
Metabolism
24 18 Inflammatory Disease, Renal and Urological Disease, Amino Acid
Metabolism
10dpi 34 23 Carbohydrate Metabolism, Lipid Metabolism, Small Molecule
Biochemistry
31 21 Antigen Presentation, Cell-To-Cell Signaling and Interaction, Cellular
Function and Maintenance
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but not in line 63 are possibly related to MD-susceptibil-
ity (Figure 2A). Genes differentially expressed after
MDV infection in all three chicken lines are likely indi-
cators of a common host response to virus infection.
Finally, genes that are differentially expressed only in
one chicken line could be part of a line-specific host
response to virus infection (Figure 2A).
From the above intuition, we were able to narrow the
list of putative genes contributing to resistance (resistant
genes) to 78 and 30 and the number of genes possibly
associated with susceptibility (susceptible genes) to 78
and 43 at 10dpi, 21dpi respectively (Figure 2B-D). For
some of the putative resistant genes, the fold change
after MDV infection in RCS-M is about half or less
compared to line 63 suggesting an additive effect of
these genes in resistance (Additional file 4. Table S3).
We can also find several genes that show a similar beha-
viour in the susceptible gene lists (Additional file 4.
Table S3). This is consistent with the intermediate
tumor incidence rates we observed in RCS-M chickens.
Although we were able to limit the number of putative
resistant and susceptible genes, it is still a difficult task
to determine the most important genes. By further ana-
lysing the networks associated with these genes, we
found several genes involved in a large number of bio-
functions (Additional file 5. Table S4). This indicated
the importance of these genes to MD resistance or sus-
ceptibility even though they may not have very high fold
changes. We defined high-confidence genes as those
involved in more than 5 biofunctions to obtain high-
confidence gene lists important for MD-resistance or
-susceptibility (Table 3). The differentially expressed
genes at the various time points were different indicat-
ing different mechanisms involved in the host response.
At 10 dpi several interleukin genes were present among
the putative susceptible genes such as IL8, IL17A and
IL12RB2. The NOS2 gene, which can catalyze the gen-
eration of NO (nitric oxide), was also found in the puta-
tive MD-susceptible gene list.
Validation of the microarray results by real-time
quantitative PCR
To validate the microarray results, we designed primers
for some high-confidence genes such as CD8a, CTLA4,
IL8 and USP18 and some other genes chosen at
Table 2 Enriched networks at different time points of MDV infection in different chicken lines (Continued)
29 20 Molecular Transport, Drug Metabolism, Lipid Metabolism
21 16 Carbohydrate Metabolism, Drug Metabolism, Small Molecule
Biochemistry
20 16 Dermatological Diseases and Conditions, Genetic Disorder,
Immunological Disease
21dpi 33 23 Cell Morphology, Cellular Assembly and Organization, Cell-To-Cell
Signaling and Interaction
26 19 Connective Tissue Development and Function, Skeletal and Muscular
System Development and Function, Tissue Morphology
24 18 Carbohydrate Metabolism, Small Molecule Biochemistry, Organismal
Functions
24 23 Cell Death, Gene Expression, Cellular Function and Maintenance
23 18 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry
*The genes input in IPA software were obtained using P < 0.05, |LogFC|>1.5 and FDR<0.5.
Figure 2 Venn diagram of the differentially expressed genes
after MDV infection in different chicken lines at three time
points showing the number of genes that are related to MD-
resistance and -susceptibility. A. Schema showing the gene sets
related to MD-resistance and-susceptibility. R: genes related to MD-
resistance; S: genes related to MD-susceptibility; U: line specific
genes; N: genes with no definition. B. 10 days post infection. C. 21
days post infection. Line 63.non: non-infected control of line 63
chickens; Line 63.inf: infected line 63 chickens; Line 72.non: non-
infected control of line 72 chickens; Line 72.inf: infected line 72
chickens; RCS-M.non: non-infected control of RCS-M; RCS M.inf:
infected RCS-M chicken.
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Table 3 Genes from MD-resistant and -susceptible gene lists enriched in more than 5 biofunctions
T.
Point
R./
S.
Genes +/- No.
Bio.
P.Name S. Name Description
10dpi R. GNAQ - 39 *002455 AJ851735 Q5F3B5 : (Q5F3B5) Hypothetical protein
R. PRKG1 - 33 *015981 BU421057 Q9Z0Z0 : (Q9Z0Z0) cGMP-dependent protein kinase 1, beta isozyme (CGK 1 beta)
(cGKI-beta)
R. CD8A + 27 *007686 CR390735 XP_420863 : gi:50747402:ref:XP_420863.1: PREDICTED: similar to CD8 alpha chain
[Gallus gallus]
R. RGS4 - 27 A_87_P021537 BX950639 Gallus gallus finished cDNA, clone ChEST606e8. [BX950639]
R. RARB - 25 A_87_P008918 X56674 Chicken mRNA for retinoic acid binding protein beta isoform. [X56674]
R. HAS3 + 12 *013355 BU278152 Q8CEB9 : (Q8CEB9) Mus musculus 10 days neonate skin cDNA, RIKEN full-length
enriched library, clone:4732404L04 product:similar to DG42III
R. SPINK5 - 12 *005267 CR353088 P10184 : gi:1708509:sp:P10184:IOV7_CHICK Ovoinhibitor precursor &gt;gnl:
BL_ORD_ID:146450 gi:212485:gb:AAA48994.1: ovoinhibitor
R. SULF2 - 10 A_87_P022688 BX934216 Gallus gallus finished cDNA, clone ChEST442e20. [BX934216]
R. COL14A1 - 9 A_87_P008851 X70793 G.domesticus mRNA for collagen XIV (longer splice variant). [X70793]
R. SCN4B - 9 A_87_P021873 BX935954 Gallus gallus finished cDNA, clone ChEST430l23. [BX935954]
R. WISP1 - 9 A_87_P009711 DQ003338 Gallus gallus WNT1 inducible signaling pathway protein 1 (WISP-1) mRNA,
complete cds. [DQ003338]
R. AHNAK - 5 *004305 BX935083 NP_033773 : gi:61743961:ref:NP_033773.1: AHNAK nucleoprotein isoform 1 [Mus
musculus]
R. P4HA2 - 5 A_87_P007103 TC198023 Q8BU53 (Q8BU53) Mus musculus 2 days pregnant adult female oviduct cDNA,
RIKEN full-length enriched library, clone:E230038K10 product:procollagen-proline,
2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha II polypeptide, full
insert sequence, p
S. NOS2 + 64 A_87_P009073 U46504 Chicken macrophage nitric oxide synthase mRNA. [U46504]
S. IL8 - 58 *010230 Y14971 O73912 : (O73912) K60 protein precursor (CXC chemokine K60)
S. IL17A + 53 A_87_P035017 AY920750 Gallus gallus interleukin 17 mRNA, complete cds. [AY920750]
S. CTLA4 + 47 *019882 DN853042 XP_421960 : gi:50750341:ref:XP_421960.1: PREDICTED: similar to costimulatory
molecule B7 receptor CD152 [Gallus gallus]
S. IL12RB2 + 23 *000640 AJ621939 Q5GR16 : (Q5GR16) Interleukin 12 receptor beta 2 (Fragment)
S. PLK1 + 20 *001748 AJ720598 Q5ZJ36 : (Q5ZJ36) Hypothetical protein
S. ROR1 - 13 *000634 AJ620298 Q705C2 : (Q705C2) Tyrosine kinase orphan receptor 1
S. LECT2 - 11 *009802 M29449 O88803 : (O88803) Leukocyte cell-derived chemotaxin 2 precursor
(Chondromodulin II) (ChM-II)
S. ABCA8 - 6 *016305 BU440826 XP_415691 : gi:50757881:ref:XP_415691.1: PREDICTED: similar to ATP-binding
cassette, sub-family A, member 10; ATP-binding cassette A10 [Gallus gallus]
S. TSPAN8 - 6 *004228 BX934864 XP_416096 : gi:50728338:ref:XP_416096.1: PREDICTED: similar to Tm4sf3 protein
[Gallus gallus]
S. COL5A2 - 6 A_87_P001489 TC224310 Q86XF6 (Q86XF6) COL5A2 protein, partial (5%) [TC224310]
R. MMP9 - 63 A_87_P037769 AF222690 Gallus gallus 75 kDa gelatinase mRNA, complete cds. [AF222690]
21dpi R. SFTPA1 + 38 *000489 AF411083 Q90XB2 : (Q90XB2) Surfactant protein A precursor
R. FBXW4 - 6 *015952 BU419266 Q9JMJ2 : (Q9JMJ2) F-box/WD-repeat protein 4 (F-box and WD-40 domain protein
4) (Hagoromo protein)
R. CPN1 - 5 *006641 CR387490 Q9EQV8 : (Q9EQV8) Carboxypeptidase N, polypeptide 1, 50kD
S. CD28 + 50 *010136 X67915 P31043 : (P31043) T-cell-specific surface glycoprotein CD28 homolog precursor
(CHT28)
S. CHRM4 - 37 A_87_P009241 NM_001031191 Gallus gallus cholinergic receptor, muscarinic 4 (CHRM4), mRNA [NM_001031191]
S. F10 - 29 *009605 D00844 P25155 : (P25155) Coagulation factor × precursor (Stuart factor) (Virus activating
protease) (VAP)
S. WNT7A - 27 A_87_P038155 AB045629 Gallus gallus mRNA for Wnt-7a, complete cds. [AB045629]
S. FMN2 + 12 A_87_P005690 TC203559 AF218942 formin 2-like protein {Homo sapiens;}, partial (28%) [TC203559]
S. ATF6 - 8 A_87_P023703 BX931991 Gallus gallus finished cDNA, clone ChEST222o13. [BX931991]
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random, such as CD8b, GHR, TNFRSF6B and MMP2.
Since a reference gene with stable expression is essential
to avoid distortions in qPCR, the two genes GAPDH
and ACTB are commonly used as internal reference for
doing qPCR of MDV infected samples [24,27]. In our
validation, we first used both genes as internal refer-
ences to see if there were any distortions and found no
differences (Additional file 6. Figure S2). Therefore,
GAPDH was chosen as the internal reference. We also
designed primers that span introns to further avoid the
influence of DNA contamination. As shown in
Additional file 2. Figure S1, we were able to validate
most of the genes that are differentially expressed. Also,
comparable expression profiles were observed for most
of the validated genes in the microarray and qPCR
(Table 4) which further suggested that the gene expres-
sion profiles from the microarray are reliable.
Discussion
There have been several studies looking at gene expres-
sion changes related to disease in general [28-30] and
MD in particular [24,27,31-34], although results tend to
Table 3 Genes from MD-resistant and -susceptible gene lists enriched in more than 5 biofunctions (Continued)
S. GLO1 - 6 *004233 BX934880 XP_419481 : gi:50740506:ref:XP_419481.1: PREDICTED: similar to glyoxylase 1;
glyoxalase 1 [Gallus gallus]
S. OPN4 - 5 *002725 AY882944 XP_421494 : gi:50749124:ref:XP_421494.1: PREDICTED: similar to Opsin 4
(Melanopsin) [Gallus gallus]
S. ITGBL1 - 5 *016603 BU449144 Q4VBJ0 : (Q4VBJ0) Integrin, beta-like 1
T.Point: time point; No. Bio.: number of biofunctions involved; P.Name: Probe Name; S.Name: Systematic Name; R.: resistant genes; S.: susceptible genes; +: up-
regulated; -:down-regulated.
Table 4 Validation of microarray results by quantitative PCR
Genes Probe Name in Micro-array Time
points
Gene expression fold change after MDV infection in each lines
(Inf./Non.)
line 63 line 72 RCS-M
Micro-
array
Q-PCR Micro-
array
Q-PCR Micro-Array Q-PCR
5dpi 1.02 1.45 2.85 4.07 1.41 1.29
CTLA-4 *019882 10dpi 2.31 3.37 3.29 13.68 3.56 7.02
21dpi 0.62 2.05 3.07 2.03 1.27 1.44
5dpi 1.46 1.05 1.41 1.19 1.52 0.85
CD8a *007686 10dpi 2.92 2.33 1.51 1.35 3.90 2.80
21dpi 1.08 3.13 0.35 0.05 1.24 2.01
5dpi 1.17 1.14 1.07 0.97 1.14 0.78
CD8b A_87_P008699 10dpi 1.87 2.86 1.03 2.05 1.86 2.30
21dpi 1.42 3.31 0.32 0.04 1.10 2.03
5dpi 1.24 3.37 4.09 4.13 1.43 1.68
USP18 *005670 10dpi 2.07 2.15 4.87 5.55 2.53 0.58
21dpi 0.98 11.89 3.28 4.54 2.73 5.99
5dpi 1.00 2.85 5.67 9.36 1.12 4.17
TNFRSF6B *003404 10dpi 5.03 9.47 5.52 11.46 2.75 2.35
21dpi 1.54 5.27 4.28 9.14 1.00 6.85
5dpi 1.00 0.64 0.60 0.28 0.62 0.29
MMP2 A_87_P009159 10dpi 0.78 0.89 0.63 0.93 0.54 0.62
21dpi 0.88 1.10 0.22 0.02 0.82 1.16
5dpi 1.00 0.72 1.04 0.18 1.71 0.91
IL8 *010230 10dpi 8.28 0.66 3.01 0.19 4.25 0.10
21dpi 18.51 2.22 0.46 0.02 0.81 2.59
5dpi 1.00 3.14 1.00 0.45 1.85 0.81
GHR A_87_P009190 10dpi 8.57 1.25 0.24 1.82 1.00 0.53
21dpi 1.54 1.56 0.40 0.59 1.00 2.76
The numbers here represent the fold change of gene expression after MDV infection. The numbers equal to 1.00 means the expression level doesn’t change
after MDV infection. The numbers > 1.00 means the expression level is increased after MDV infection while numbers < 1.00 indicate that the expression level is
reduced after MDV infection. The numbers in bold and italic are statistically significant (P < 0.05).
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vary a lot. MD is a complex disease with the disease
phenotype in susceptible individuals depending on the
location and frequency of tumors. Any single gene with
differential expression cannot fully explain the phenom-
enon of host resistance or susceptibility. Therefore, we
tried to use a genome-wide approach to build on the
current understanding of Marek’s disease pathogenesis
and immune response to MDV. Upon close examination
of the transcriptional responses, dramatically increased
numbers of significant genes were observed at 10dpi in
RCS-M and at 21dpi in line 72 at lower FDR levels
(FDR < 0.2) which indicated a strongly enhanced tran-
scriptional response. At a more relaxed FDR level (FDR
< 0.5), we find comparable numbers of differentially
expressed genes at 5, 10 and 21dpi in line 63 and RCS-
M. Line 72 has similar numbers of significant genes at
10dpi but there is a definite increase in the transcrip-
tional response at 21dpi with close to twice as many dif-
ferentially expressed genes. However, even at this level,
we do not find any significantly expressed genes at 5dpi
in line 72 (FDR<0.5), indicating a much muted transcrip-
tional response (Table 1).
Over the years, several attempts have been made to
identify the gene profiles that change as a result of
MDV infection. For example, using microarray analysis,
studies have identified some genes related to MDV
infection by using different chicken lines and MDV
strains [24,31-34]. When chicken embryo fibroblasts
were infected with MDV, genes related to inflammation,
cell-growth and differentiation and antigen presentation,
such as MIP, IL-13R, MHC I and MHC II were induced
both at 2dpi and 4dpi [33]. In contrast, in spleen tissue,
several other genes were found to be affected at an early
stage, including TLR-15, IL-6 and Mx1[31]. In chickens
with major histocompatibility complex (MHC)-asso-
ciated MD resistance, the immunoglobulin genes IgG
and IgM were differentially expressed after MDV infec-
tion at 7dpi and 14dpi[24], whereas in lines 6 and 7
from ADOL, that carry the same MHC haplotype (B2)
but differ in their response to MDV infection[35], var-
ious alloantigens like Ly-4 [16] and Bu-1 [17] were dif-
ferentially expressed. Linkage and association studies as
well as integrated analyses using genetic mapping and
microarrays have revealed some genes that may be
responsible for MD progression or resistance, such as
GH, IFNg and SULT [27]. However, it is difficult to find
a consensus amongst these studies due to variation in
experimental parameters such as, virus strain or in vitro
derived samples. By using a genome-wide approach and
three chicken lines with varying resistance to MD, we
were able to generate a comprehensive list of candidate
genes that can be used for studying MD-resistance and
susceptibility. Besides finding some genes that were
reported in previous studies, such as Mx1, we also
found several genes that have not been reported before
in this context, such as CD8a, IL8, USP18, and CTLA4.
CD8a, present in the putative resistant gene list at
10dpi, codes a surface glycoprotein expressed on a sub-
population of cytotoxic T lymphocytes (CTLs) [36],
which binds to the a3 domain or membrane-proximal
domain of most of the known HLA class I molecules to
enhance CTL activation [37-41]. It has been shown that
CD8a was up-regulated by MDV infection at the early
cytolytic stage (4dpi and 7dpi), whereas IgM and CD3
were down-regulated [34]. These are similar to our
microarray results, the slight difference being possibly
due to the differences in virus strains and genetic back-
ground of the chickens. The CD8a gene was signifi-
cantly up-regulated at 10dpi in the MD-resistant
chicken line (line 63) and RCS-M, but down-regulated
in the MD-susceptible chicken line (line 72). In chickens
vaccinated against MDV an increase of CD8a cells was
found after MDV infection compared to unvaccinated
chickens [32]. The vaccinated birds were phenotypically
similar to line 63 and hence, this result is consistent
with our finding. The above evidence, taken all together,
leads us to speculate that CD8a plays an important role
in MD resistance. The induction of CD8a gene may
result from an increase of the CD8+ T cells that elimi-
nate MDV infected cells in the resistant chickens. How-
ever, this scenario needs further validation.
In contrast, CTL-associated antigen-4 (CTLA-4), pre-
sent in our putative susceptible gene list at 10dpi, is a
member of the immunoglobulin superfamily expressed
on the surface of an activated T cell [42]. It has been
reported that the knockout of CTLA-4 resulted in a
lymphoproliferative disorder and death in mice, which
indicated a very important role of CTLA-4 in negative
regulation of T cell activation [43]. The blockade of the
CTLA-4 pathway results in a rejection of tumor [44,45],
indicating that a lower CTLA-4 expression may be
important for antitumor response. Therefore, in
humans, a current strategy of immunotherapy focuses
on the blockade of the CTLA-4 pathway [46,47]. A
higher expression of CTLA-4 was detected at lymphoma
lesions in MD-susceptible chickens at 21dpi, although
no significant difference was found in the whole tissue
[48]. Importantly, a similar result existed in our data:
the fold change of CTLA-4 at 10dpi after MDV infection
is much less in line 63 than in line 72 and RCS-M (Table
4), indicating a lower level of CTLA-4 involved in anti-
tumor immune response.
In addition to the above genes, some networks and
biofunctions were also observed to be different between
MD-resistant and susceptible chickens. It is interesting
to note that most of the differentially expressed genes
were not enriched in biofunctions of immune related
diseases, but with other diseases or metabolism. This is
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consistent with the fact that apart from the generation
of tumors, MD-susceptible chickens also exhibit weight
loss, paralysis and other symptoms. However, some
immune response-related biofunctions were enriched
only in line 63 and RCS-M chickens. It was thought for
a long time that tumor cells have no antigen and this
enables them to escape the host immune system. While
the finding of the melanoma antigen in the late 1980’s
shed light on the role of immune system to fight against
tumors [49], the tumor cells are known to also have
immunosuppressive agents that help them evade detec-
tion and killing by the immune system [50,51]. The net-
works related to immune response found in line 63
chickens, suggests that in these chickens the immune
system is activated to counteract the development of
tumor. In contrast, the transformed cells in susceptible
chickens are able to escape the natural resistance of the
immune system to generate tumors, although at present
it is still unclear if this is due to a larger initial damage
to the immune system [52] or the immunosuppression
induced by MDV in line 72 chickens. NOS2 is an
enzyme that catalyzes the generation of NO [53] which
in turn increases the virulence of MDV by immunosup-
pression [54]. However, it has also been shown that NO
has inhibitory effects on MDV replication [55] and NO
production in MDV-infected susceptible chickens
(MHC, B13B13) is the lowest in comparison to MD-
infected resistant birds (MHC, B19B19) [55,56]. Interest-
ingly, we found that the NOS2 gene was up-regulated in
susceptible chicken lines. Therefore, it remains to be
seen whether the up-regulation of NOS2 in line 72 could
induce immunosuppression and increase the risk of
tumor generation in MD-susceptible chickens. The
above results indicate that different immune response in
resistant and susceptible chickens lead to the vastly dif-
ferent responses to MDV infection.
To minimize transcriptional variations and take full
advantage of a similar genetic background in the inbred
lines, we paired birds by line and dpi, respectively, and
tested the difference between infected and non-infected
individuals. This procedure not only led us to identify
the genes most likely related to MD resistance and sus-
ceptibility, but also revealed a common broad influence
of MDV infection on the hosts. By using IPA to analyze
differentially expressed gene sets, we found focused
pathways enriched in metabolism, tissue development,
gene expression and cell cycle along with other
immune-related pathways preferentially enriched in
resistant chickens. These results suggested possible
mechanisms and specific genes related to MD-resistance
or -susceptibility. We hypothesized that there are four
possible causes behind MD-resistance: some genes acti-
vated in resistant chickens can (i) cause loss of the
MDV receptor, (ii) help to clear infected cells, (iii) affect
the viral life cycle or (iv) prevent transformation of
infected cells. Our observations and previous research
have showed that the virus load in both resistant and
susceptible chickens was similar at early stages of infec-
tion [18,57], suggesting the presence of receptors for
MDV in both resistant and susceptible chickens. Thus,
the latter three of the aforementioned possibilities are
more likely to be the main reasons for MD-resistance
although it is not easy to say which of these play a big
role in non-MHC associated resistance.
Conclusions
Using a comprehensive genome-wide study of gene
expression in chicken lines with varying resistance to
MD, we were able to identify pathways and genes that
may be involved in MD-resistance and susceptibility.
Phenotypic similarities between the chicken lines
enabled us to narrow the list of putative genes to 108
genes associated with MD-resistance and 121 genes
associated with susceptibility. Combining network analy-
sis with differential gene expression analysis helped
uncover high-confidence genes such as CD8a, IL8,
USP18, and CTLA-4 and several immune-related bio-
functions with potentially important consequences to
MDV infection. Our findings add to the current under-
standing of the mechanism behind resistance and sus-
ceptibility to MD while expanding the scope of future
studies with a comprehensive list of putative genes. Our
approach also underlines the importance of comprehen-
sive functional studies to gain valuable biological insight
into the genetic factors behind complex disease.
Methods
Sample Collection for Microarray
Three inbred lines of White Leghorn (line 63, line 72
and RCS-M) were divided into two treatment groups
each containing 60 chickens. One group from each line
was infected with a partially attenuated very virulent
strain (vv+) of MDV-648A passage 40 [1], at day 5 after
hatch, intra-abdominally at a viral dosage of 500 plaque-
forming units (PFU) per chick. The other group was not
infected. The viral-challenge experiment was conducted
in the BL-2 facility at ADOL. Four chickens from each
group were euthanized at 5dpi (cytolytic infection per-
iod), 10dpi (latency period) and 21dpi (reactivation per-
iod), respectively. Spleen samples were collected and
stored in RNAlater solution (Qiagen, Valencia, CA,
USA) at -20°C until RNA extraction. All the experimen-
tal chickens were managed and euthanized following
ADOL’s Guidelines for Animal Care and Use (revised
April, 2005) and the Guide for the Care and Use of
Laboratory Animals published by Institute for Labora-
tory Animal Research (ILAR Guide) in 1996 (http://
www.nap.edu/openbook.php?record_id=5140).
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RNA Extraction
Approximately 30~50mg spleen tissues were homoge-
nized in TRizol Reagent (Invitrogen, Frederick, MD,
USA), and total RNA extraction was performed accord-
ing to the manufacturer’s instructions (Invitrogen, Fre-
derick, MD, USA). Total RNA was purified using the
RNAeasy mini column (Qiagen, Valencia, CA, USA) and
contaminant DNA was digested by DNase I (Qiagen,
Valencia, CA, USA). RNA concentration was assessed
using Nanodrop ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA) and RNA quality
determined by 2100 Bioanalyzer (Agilent, Foster City,
CA, USA).
Microarray Experiment Design, Hybridization and Analysis
Custom Agilent 4 × 44K chicken microarrays were used
in this study. The 4 × 44K chicken arrays were designed
based on the whole chicken genome sequence and con-
sist of 42,034 probes [58]. Four biological replicates of
each group were carried out at each time point. RNA
was labelled using the Agilent Quick-Amp labelling kit
(Agilent Technologies, Santa Clara, CA, USA). In two of
the four replicates of each experimental group, the
infected samples were labelled with Cy3 and the unin-
fected two were labelled with Cy5. A total of 825 ng of
Cy3 and Cy5 labelled cDNAs were then hybridized to
the 4 × 44K Agilent chicken arrays. Following stringency
washes, slides were scanned on an Agilent G2505B
microarray scanner and the resulting image files ana-
lyzed with Agilent Feature Extraction software (version
9.5.1). All procedures were carried out according to the
manufacturer’s protocols. After the microarray analysis
was performed in three chicken lines at three time
points, we first tested for the presence of outliers (JMP
Genomics, Version 9). Parallel plots and PCA revealed
the presence of outliers in our datasets, which were sub-
sequently removed. A parallel plot subsequently indi-
cated that the log2 intensities had similar distributions
across all remaining arrays (Additional file 7. Figure S3).
After the initial quality assessment step we performed
linear modelling using the limma package in R to find
differentially expressed genes. Dye bias was removed by
normalizing within array using loess normalization [59]
and normalization between arrays was carried out using
quantile normalization [60]. The p-values were corrected
for multiple comparisons using the Benjamini-Hochberg
FDR calculation procedure [26]. We compared age-
matched individuals from the same line before and after
infection with MDV at three time points of disease pro-
gression. All the array data discussed in this publication
have been deposited in NCBI’s Gene Expression Omni-
bus (Yu et al., 2010) and are accessible through GEO
Series accession number GSE24017 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE24017).
Data Mining and Network Analysis
The expressed sequence tags (ESTs) specific to microar-
ray probes were mapped to proteins or protein homo-
logs with GenBank names, Swissprot, pfam or RefSeq
accession numbers using the BioMart data mining sys-
tem via Sigenae (Details found on http://www.sigenae.
org). Proteins with the identity of 40% or more were
considered to be homologs [61]. In case of multiple pro-
teins mapping to a probe, proteins with the highest
identity were used to create a unique mapping. The
resultant list was then analyzed using IPA to detect the
enrichment of biofunctions and networks. Core analysis
was performed in IPA using significantly expressed
genes from the statistical analysis based on the Ingenuity
Knowledge Base with the reference set “Genes + Endo-
genous Chemicals”.
Quantitative Real-time RT-PCR
RNA samples for quantitative real-time PCR were used
for first strand cDNA synthesis using 1 μg of total RNA
by SuperScript™ II Reverse Transcriptase (Invitrogen,
Frederick, MD, USA) with oligo (dT)12-18 primers (Invi-
trogen, Frederick, MD, USA). Samples were then ana-
lyzed with real time RT-PCR using an iCycler iQ PCR
system (Bio-Rad, Hercules, CA, USA). The real time
RT-PCR reactions were performed in a final volume of
20 μl with the QuantiTect SYBR Green PCR Kit (Qia-
gen, Valencia, CA, USA) according to the manufac-
turer’s instructions. Each group has 4 biological
replicates with 3 replicates for one reaction and each
reaction was repeated twice. The mRNA expression was
normalized against the housekeeping gene GAPDH (gly-
ceraldehyde-3-phosphate dehydrogenase). The primers
for all the genes analyzed are in Additional file 8. Table
S5. All steps of our Q-PCR validation, which include
RNA extraction, cDNA synthesis, reference gene selec-
tion, Q-PCR procedures, and data analysis were per-
formed according to the Minimum Information for
Publication of Quantitative PCR Experiments (MIQE)
guidelines [62]
Additional material
Additional file 1: Table S1. Number of genes differentially
expressed after MDV infection including MDV genes. This table
contains the number of genes that are differentially expressed after MDV
infection which including all the genes that were shown in the
microarray like MDV genes. Genes with differential expression were
termed with p < 0.05, LogFC>1.5 and FDR < 0.5. +: up-regulated after
MDV infection; -: down-regulated after MDV infection.
Additional file 2: Figure S1. Validation of microarray data by Q-PCR.
This figure showing the Q-PCR validation result of the genes that shown
significant different expression after MDV infection in three time points
(5dpi, 10dpi, and 21dpi). Line 63.non: non-infected control of line 63
chickens; Line 63.inf: infected line 63 chickens; Line 72.non: non-infected
control of line 72 chickens; Line 72.inf: infected line 72 chickens; non:
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non-infected control of chicken; inf: infected RCS-M chicken. n = 4 for
each line. *P < 0.05, **P < 0.01.
Additional file 3: Table S2. Homologs of chicken ESTs from BioMart.
This table includes the homologs that were converted from the chicken
ESTs on the microarray. The data mining was down on BioMark (details
see http://www.sigenae.org).
Additional file 4: Table S3. Possible MD-resistant and susceptible
gene lists at 10dpi and 21dpi. This table showed the possible
candidates for MD-resistance and susceptibility at 10dpi and 21dpi. The
gene lists were chosen by the following criteria: Genes differentially
expressed after MDV infection and having similar trends in line 63 and
RCS-M but not in line 72 are likely to be related to MD-resistance;
conversely, genes showing similar trends in line 72 and RCS-M but not in
line 63 are possibly related to MD-susceptibility.
Additional file 5: Table S4. Biofunction enrichment of the MD-
resistant and susceptible genes at 10dpi and 21dpi. The genes that
are listed as possible MD-resistant and -susceptible genes were used to
do the IPA analysis. This table showed the biofunctions that were
enriched by these genes at 10dpi and 21dpi.
Additional file 6: Figure S2. Stability test of the internal reference.
ACTB gene was added to normalize the gene expression when doing
the Q-PCR experiment to monitor the stability of the Q-PCR result when
using GAPDH as the internal control. A similar ratio shown in both
normalization method indicated a stabilized system of the Q-PCR.
Additional file 7: Figure S3. A parallel plot of kernel densities shows
similar distribution of log2 intensities in all arrays after
normalization.
Additional file 8: Table S5. Primers for validation of microarray
results by quantitative PCR.
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